Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYNOTE-062: Pembrolizumab in advanced gastric/GEJ cancer
NCT02494583Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Jul 2015
- Primary completion
- Mar 2019
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
01
Overview
A Phase 3 trial of pembrolizumab in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by Merck & Co.. Started Jul 2015; status: completed.
02
Drugs
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT02494583.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02494583.